Literature DB >> 28314854

Common nonmutational NOTCH1 activation in chronic lymphocytic leukemia.

Giulia Fabbri1, Antony B Holmes1, Mara Viganotti1, Claudio Scuoppo1, Laura Belver1, Daniel Herranz1, Xiao-Jie Yan2, Yasmine Kieso2, Davide Rossi3,4, Gianluca Gaidano5, Nicholas Chiorazzi2, Adolfo A Ferrando1,6,7, Riccardo Dalla-Favera8,6,9,10.   

Abstract

Activating mutations of NOTCH1 (a well-known oncogene in T-cell acute lymphoblastic leukemia) are present in ∼4-13% of chronic lymphocytic leukemia (CLL) cases, where they are associated with disease progression and chemorefractoriness. However, the specific role of NOTCH1 in leukemogenesis remains to be established. Here, we report that the active intracellular portion of NOTCH1 (ICN1) is detectable in ∼50% of peripheral blood CLL cases lacking gene mutations. We identify a "NOTCH1 gene-expression signature" in CLL cells, and show that this signature is significantly enriched in primary CLL cases expressing ICN1, independent of NOTCH1 mutation. NOTCH1 target genes include key regulators of B-cell proliferation, survival, and signal transduction. In particular, we show that NOTCH1 transactivates MYC via binding to B-cell-specific regulatory elements, thus implicating this oncogene in CLL development. These results significantly extend the role of NOTCH1 in CLL pathogenesis, and have direct implications for specific therapeutic targeting.

Entities:  

Keywords:  NOTCH1; chronic lymphocytic leukemia; transcriptional network

Mesh:

Substances:

Year:  2017        PMID: 28314854      PMCID: PMC5389283          DOI: 10.1073/pnas.1702564114

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  83 in total

1.  Transcriptional analysis of the B cell germinal center reaction.

Authors:  Ulf Klein; Yuhai Tu; Gustavo A Stolovitzky; Jeffrey L Keller; Joseph Haddad; Vladan Miljkovic; Giorgio Cattoretti; Andrea Califano; Riccardo Dalla-Favera
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-25       Impact factor: 11.205

2.  Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia.

Authors:  Davide Rossi; Silvia Rasi; Giulia Fabbri; Valeria Spina; Marco Fangazio; Francesco Forconi; Roberto Marasca; Luca Laurenti; Alessio Bruscaggin; Michaela Cerri; Sara Monti; Stefania Cresta; Rosella Famà; Lorenzo De Paoli; Pietro Bulian; Valter Gattei; Anna Guarini; Silvia Deaglio; Daniela Capello; Raul Rabadan; Laura Pasqualucci; Riccardo Dalla-Favera; Robin Foà; Gianluca Gaidano
Journal:  Blood       Date:  2011-11-10       Impact factor: 22.113

3.  An activating intragenic deletion in NOTCH1 in human T-ALL.

Authors:  J Erika Haydu; Kim De Keersmaecker; Mary Kaye Duff; Elisabeth Paietta; Janis Racevskis; Peter H Wiernik; Jacob M Rowe; Adolfo Ferrando
Journal:  Blood       Date:  2012-04-17       Impact factor: 22.113

4.  High-throughput chromatin immunoprecipitation for genome-wide mapping of in vivo protein-DNA interactions and epigenomic states.

Authors:  Ronnie Blecher-Gonen; Zohar Barnett-Itzhaki; Diego Jaitin; Daniela Amann-Zalcenstein; David Lara-Astiaso; Ido Amit
Journal:  Nat Protoc       Date:  2013-02-21       Impact factor: 13.491

5.  Super-enhancers in the control of cell identity and disease.

Authors:  Denes Hnisz; Brian J Abraham; Tong Ihn Lee; Ashley Lau; Violaine Saint-André; Alla A Sigova; Heather A Hoke; Richard A Young
Journal:  Cell       Date:  2013-10-10       Impact factor: 41.582

6.  Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Authors:  Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-30       Impact factor: 11.205

7.  Selective inhibition of tumor oncogenes by disruption of super-enhancers.

Authors:  Jakob Lovén; Heather A Hoke; Charles Y Lin; Ashley Lau; David A Orlando; Christopher R Vakoc; James E Bradner; Tong Ihn Lee; Richard A Young
Journal:  Cell       Date:  2013-04-11       Impact factor: 41.582

8.  High-resolution genomic profiling of chronic lymphocytic leukemia reveals new recurrent genomic alterations.

Authors:  Jennifer Edelmann; Karlheinz Holzmann; Florian Miller; Dirk Winkler; Andreas Bühler; Thorsten Zenz; Lars Bullinger; Michael W M Kühn; Andreas Gerhardinger; Johannes Bloehdorn; Ina Radtke; Xiaoping Su; Jing Ma; Stanley Pounds; Michael Hallek; Peter Lichter; Jan Korbel; Raymonde Busch; Daniel Mertens; James R Downing; Stephan Stilgenbauer; Hartmut Döhner
Journal:  Blood       Date:  2012-10-09       Impact factor: 22.113

9.  EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation.

Authors:  Wendy Béguelin; Relja Popovic; Matt Teater; Yanwen Jiang; Karen L Bunting; Monica Rosen; Hao Shen; Shao Ning Yang; Ling Wang; Teresa Ezponda; Eva Martinez-Garcia; Haikuo Zhang; Yupeng Zheng; Sharad K Verma; Michael T McCabe; Heidi M Ott; Glenn S Van Aller; Ryan G Kruger; Yan Liu; Charles F McHugh; David W Scott; Young Rock Chung; Neil Kelleher; Rita Shaknovich; Caretha L Creasy; Randy D Gascoyne; Kwok-Kin Wong; Leandro Cerchietti; Ross L Levine; Omar Abdel-Wahab; Jonathan D Licht; Olivier Elemento; Ari M Melnick
Journal:  Cancer Cell       Date:  2013-05-13       Impact factor: 31.743

10.  Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.

Authors:  Andrew W Roberts; Matthew S Davids; John M Pagel; Brad S Kahl; Soham D Puvvada; John F Gerecitano; Thomas J Kipps; Mary Ann Anderson; Jennifer R Brown; Lori Gressick; Shekman Wong; Martin Dunbar; Ming Zhu; Monali B Desai; Elisa Cerri; Sari Heitner Enschede; Rod A Humerickhouse; William G Wierda; John F Seymour
Journal:  N Engl J Med       Date:  2015-12-06       Impact factor: 91.245

View more
  48 in total

Review 1.  Ontogeny, Genetics, Molecular Biology, and Classification of B- and T-Cell Non-Hodgkin Lymphoma.

Authors:  Russell James Hubbard Ryan; Ryan Alan Wilcox
Journal:  Hematol Oncol Clin North Am       Date:  2019-05-18       Impact factor: 3.722

2.  B cells with aberrant activation of Notch1 signaling promote Treg and Th2 cell-dominant T-cell responses via IL-33.

Authors:  Hiroshi Arima; Momoko Nishikori; Yasuyuki Otsuka; Wataru Kishimoto; Kiyotaka Izumi; Koubun Yasuda; Tomohiro Yoshimoto; Akifumi Takaori-Kondo
Journal:  Blood Adv       Date:  2018-09-25

Review 3.  Richter transformation in the era of novel agents.

Authors:  Wei Ding
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

4.  Bidirectional linkage between the B-cell receptor and NOTCH1 in chronic lymphocytic leukemia and in Richter's syndrome: therapeutic implications.

Authors:  Francesca Arruga; Valeria Bracciamà; Nicoletta Vitale; Tiziana Vaisitti; Katiuscia Gizzi; Alison Yeomans; Marta Coscia; Giovanni D'Arena; Gianluca Gaidano; John N Allan; Richard R Furman; Graham Packham; Francesco Forconi; Silvia Deaglio
Journal:  Leukemia       Date:  2019-08-29       Impact factor: 11.528

5.  Coactivation of NF-κB and Notch signaling is sufficient to induce B-cell transformation and enables B-myeloid conversion.

Authors:  Yan Xiu; Qianze Dong; Lin Fu; Aaron Bossler; Xiaobing Tang; Brendan Boyce; Nicholas Borcherding; Mariah Leidinger; José Luis Sardina; Hai-Hui Xue; Qingchang Li; Andrew Feldman; Iannis Aifantis; Francesco Boccalatte; Lili Wang; Meiling Jin; Joseph Khoury; Wei Wang; Shimin Hu; Youzhong Yuan; Endi Wang; Ji Yuan; Siegfried Janz; John Colgan; Hasem Habelhah; Thomas Waldschmidt; Markus Müschen; Adam Bagg; Benjamin Darbro; Chen Zhao
Journal:  Blood       Date:  2020-01-09       Impact factor: 22.113

6.  Chronic lymphocytic leukemia (CLL) risk is mediated by multiple enhancer variants within CLL risk loci.

Authors:  Huihuang Yan; Shulan Tian; Geffen Kleinstern; Zhiquan Wang; Jeong-Heon Lee; Nicholas J Boddicker; James R Cerhan; Neil E Kay; Esteban Braggio; Susan L Slager
Journal:  Hum Mol Genet       Date:  2020-09-29       Impact factor: 6.150

7.  NOTCH1 mutations are associated with high CD49d expression in chronic lymphocytic leukemia: link between the NOTCH1 and the NF-κB pathways.

Authors:  D Benedetti; E Tissino; F Pozzo; T Bittolo; C Caldana; C Perini; D Martorelli; V Bravin; T D'Agaro; F M Rossi; R Bomben; E Santinelli; F Zaja; G Pozzato; A Chiarenza; F Di Raimondo; G Del Poeta; D Rossi; G Gaidano; M Dal Bo; V Gattei; A Zucchetto
Journal:  Leukemia       Date:  2017-09-22       Impact factor: 11.528

8.  Notch activation is pervasive in SMZL and uncommon in DLBCL: implications for Notch signaling in B-cell tumors.

Authors:  Vignesh Shanmugam; Jeffrey W Craig; Laura K Hilton; Matthew H Nguyen; Christopher K Rushton; Kian Fahimdanesh; Scott Lovitch; Ben Ferland; David W Scott; Jon C Aster
Journal:  Blood Adv       Date:  2021-01-12

9.  An aberrant NOTCH2-BCR signaling axis in B cells from patients with chronic GVHD.

Authors:  Jonathan C Poe; Wei Jia; Hsuan Su; Sarah Anand; Jeremy J Rose; Prasanthi V Tata; Amy N Suthers; Corbin D Jones; Pei Fen Kuan; Benjamin G Vincent; Jonathan S Serody; Mitchell E Horwitz; Vincent T Ho; Steven Z Pavletic; Frances T Hakim; Kouros Owzar; Dadong Zhang; Bruce R Blazar; Christian W Siebel; Nelson J Chao; Ivan Maillard; Stefanie Sarantopoulos
Journal:  Blood       Date:  2017-08-29       Impact factor: 22.113

Review 10.  MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies.

Authors:  Seyed Esmaeil Ahmadi; Samira Rahimi; Bahman Zarandi; Rouzbeh Chegeni; Majid Safa
Journal:  J Hematol Oncol       Date:  2021-08-09       Impact factor: 17.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.